Vecuronium bromide

Vecuronium bromide

Vecuronium bromide is a muscle relaxant used in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a non-depolarizing neuromuscular blocking agent of intermediate duration. Vecuronium bromide works by competing with acetylcholine for receptors at the neuromuscular junction, leading to muscle relaxation. It is often preferred in patients with cardiovascular problems due to its minimal effects on heart rate and blood pressure.

Pharmacology

Vecuronium bromide acts by binding competitively to the nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting acetylcholine from binding and thus preventing muscle contraction. Its action is reversed by acetylcholinesterase inhibitors, such as neostigmine, which increase the concentration of acetylcholine at the neuromuscular junction.

Indications

Vecuronium bromide is indicated for use as an adjunct to general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used in the ICU setting for managing patients requiring mechanical ventilation.

Dosage and Administration

The dosage of vecuronium bromide varies based on the patient's weight, the desired degree of muscle relaxation, and the method of administration. It is typically administered intravenously, and its effects are seen within 2 to 3 minutes of administration.

Side Effects

Common side effects of vecuronium bromide include:

• Skin flushing
• Hypotension
• Tachycardia
• Bronchospasm
• Anaphylaxis (rare)

Prolonged use of vecuronium bromide can lead to muscle weakness and myopathy, especially in critically ill patients.

Contraindications

Vecuronium bromide is contraindicated in patients with known hypersensitivity to the drug. Caution is advised in patients with neuromuscular diseases such as myasthenia gravis, as the effects of vecuronium may be profoundly increased in these individuals.

Pharmacokinetics

Vecuronium bromide is metabolized in the liver and excreted by the kidneys. Its elimination half-life is approximately 65 to 75 minutes, but this can be prolonged in patients with hepatic or renal impairment.

History

Vecuronium bromide was introduced in the 1980s as a safer alternative to older neuromuscular blocking agents. It quickly gained popularity due to its favorable pharmacokinetic profile and minimal cardiovascular effects.

See Also

• Neuromuscular-blocking drug
• Anesthesia
• Acetylcholine receptor

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian